Can Reglan Cause Tardive Dyskinesia? What the Evidence Shows

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Warnings to Occupational Exposure Concerns

If you or someone you know has taken Reglan (metoclopramide) and developed uncontrollable movements, you may be wondering about the connection to tardive dyskinesia. Medical research has long established that certain medications can affect neurological function, and this foundational knowledge informs our understanding of Reglan's risks. This page reviews the evidence on Reglan's association with tardive dyskinesia, including FDA warnings and occupational exposure considerations.

Reglan and Tardive Dyskinesia: Clinical and Pharmacological Evidence

Reglan (metoclopramide) is a medication approved for specific gastrointestinal conditions, but its use carries a significant risk of causing tardive dyskinesia (TD), a potentially irreversible movement disorder. The U.S. Food and Drug Administration (FDA) has issued a boxed warning, the most stringent safety alert, regarding this risk. This narrative examines the clinical presentation of TD, the pharmacology of Reglan, the mechanistic pathways linking the drug to the disorder, and the adequacy of warnings and causation considerations for affected patients. Tardive dyskinesia is characterized by involuntary, repetitive movements, typically of the face, tongue, and extremities. The FDA-approved labeling for Reglan describes TD as "a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Diagnosis is primarily clinical, based on observation of these movements, and may be delayed because metoclopramide can partially suppress the signs of TD, masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan's active ingredient, metoclopramide, is a dopamine receptor antagonist. It works by blocking dopamine D2 receptors in the brain, which can lead to extrapyramidal symptoms, including TD. The boxed warning states that "the risk of developing TD increases with duration of metoclopramide treatment and total cumulative metoclopramide dosage" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This mechanism is well-documented: chronic dopamine blockade can cause supersensitivity of dopamine receptors, leading to the involuntary movements characteristic of TD. The labeling also notes that Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Real-World Evidence and Risk Context

The FDA Adverse Event Reporting System (FAERS) database provides real-world evidence of the association between Reglan and TD. As of the data available, there were 5,712 reports of tardive dyskinesia associated with Reglan, making it the most frequently reported adverse event for the drug (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). Other related movement disorders, such as extrapyramidal disorder (3,268 reports) and dystonia (2,351 reports), were also commonly reported (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). These numbers underscore the clinical significance of the risk. The adequacy of warnings regarding Reglan and TD is a critical risk anchor. The FDA has mandated a boxed warning that clearly states: "Metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning emphasizes that treatment should be for the shortest duration necessary, with periodic reassessment of the need for continued therapy. For patients with diabetic gastroparesis, the labeling advises avoiding treatment for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, despite these warnings, the FAERS data indicate that incorrect drug administration duration was reported in 719 cases (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN), suggesting that adherence to prescribing guidelines may be suboptimal. Causation considerations for affected patients involve establishing a temporal relationship between Reglan exposure and the onset of TD. The labeling advises that if signs or symptoms of TD occur, Reglan should be discontinued immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The timeline between exposure and documented harm can vary. TD may develop after months or years of treatment, but the risk increases with longer duration and higher cumulative doses. The boxed warning notes that "the risk of developing TD increases with duration of treatment and total cumulative dosage" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In some cases, TD may appear after discontinuation of the drug, as metoclopramide can suppress the signs of TD while the patient is still taking it. For patients who develop TD, the condition may be irreversible, even after stopping Reglan. The labeling states that TD is "potentially irreversible" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This underscores the importance of early detection and prompt discontinuation. However, because TD can be masked during treatment, diagnosis may be delayed, leading to prolonged exposure and greater risk of permanent harm. In summary, the evidence clearly establishes a causal link between Reglan (metoclopramide) and tardive dyskinesia. The FDA has provided robust warnings, but real-world data suggest that these warnings are not always heeded. Patients and healthcare providers must be vigilant about monitoring for signs of TD, using Reglan for the shortest possible duration, and discontinuing the drug immediately if symptoms appear. The high number of FAERS reports highlights the ongoing public health concern.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning about Reglan and tardive dyskinesia?

The FDA has issued a boxed warning stating that Reglan (metoclopramide) can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The warning emphasizes that the risk increases with duration of treatment and total cumulative dosage, and that treatment should be for the shortest duration necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

How does Reglan cause tardive dyskinesia?

Reglan's active ingredient, metoclopramide, is a dopamine receptor antagonist. It blocks dopamine D2 receptors in the brain, which can lead to extrapyramidal symptoms, including tardive dyskinesia. Chronic dopamine blockade can cause supersensitivity of dopamine receptors, resulting in involuntary movements (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the symptoms of tardive dyskinesia?

Tardive dyskinesia is characterized by involuntary, repetitive movements, typically of the face, tongue, and extremities. These movements can be disfiguring and may be irreversible even after stopping Reglan (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.